Read #NIDA Director Dr. Nora Volkow & Dr. Rita Valentino's 🆕 guest blog for the The National Institutes of Health #BRAINInitiative. In the blog, Dr. Volkow & Dr. Valentino discuss the importance of the BRAIN Initiative, its impact on NIDA's mission and the field of neuroscience, and NIDA's participation in the program over the last decade.
The National Institute on Drug Abuse (NIDA)
Research Services
North Bethesda, Maryland 82,204 followers
Comment Policy: https://nida.nih.gov/comment-policy
About us
Official LinkedIn page of The National Institute on Drug Abuse. NIDA's mission is to advance science on drug use and addiction and to apply that knowledge to improve individual and public health. Engagement ≠ Endorsement Comment Policy: https://nida.nih.gov/comment-policy Privacy Policy: https://nida.nih.gov/privacy/how-nida-uses-third-party-web-sites-applications
- Website
-
https://nida.nih.gov/
External link for The National Institute on Drug Abuse (NIDA)
- Industry
- Research Services
- Company size
- 201-500 employees
- Headquarters
- North Bethesda, Maryland
- Type
- Government Agency
- Founded
- 1974
- Specialties
- Addiction Research, Research Training, and Research Funding
Locations
-
Primary
Three White Flint North
11601 Landsdown Street
North Bethesda, Maryland 20892, US
-
251 Bayview Boulevard
Baltimore, MD 21224, US
Employees at The National Institute on Drug Abuse (NIDA)
Updates
-
🚨 Attention prospective applicants! 🚨 Join upcoming virtual Office Hours with The National Institutes of Health Staff to learn about funding opportunities in the Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA) Program at #NIDA! Ask questions about the application & review process for RFA-DA-25-037 (U01 Clinical Trial Not Allowed) and RFA-DA-25-038 (U24 Clinical Trial Not Allowed). 🗓️ Oct. 15, 11 AM-12 PM ET 🗓️ Oct. 17, 1-2 PM ET For more information, visit: https://lnkd.in/eJYmiaiV
Researchers, check out two 🆕 The National Institutes of Health funding opportunities: Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk. 📆 Letters of intent are due October 7. Applications are due November 7. RFA-DA-25-037 (U01 Clinical Trial Not Allowed): https://lnkd.in/gE3gsZB7 📆 Letters of intent are due November 4. Applications are due December 3. RFA-DA-25-038 (U24 Clinical Trial Not Allowed): https://lnkd.in/gYBEZdep
-
National Drug and Alcohol Facts Week® takes place March 17-23, 2025. Join the conversation on substance use prevention and empower youth in making informed health decisions. Register and start planning your event today! https://go.nih.gov/KjzSG1U
-
Medications for opioid use disorder can prevent and reverse overdose. They also reduce opioid use and cravings. They are safe, effective, and save lives. The #NIDA infographic below 👇 shows how these medications work. View and share: https://go.nih.gov/1nClMYU
-
Can substance use disorder be prevented? #NIDA dedicates research to developing effective, sustainable, and scalable strategies to prevent substance use, misuse, and progression: https://go.nih.gov/Wxvkp7o #SubstanceUsePreventionMonth
Prevention | National Institute on Drug Abuse
-
🆕 from #NIDA: Higher doses of buprenorphine may improve treatment outcomes for people with opioid use disorder. The National Institutes of Health-funded analysis, published in JAMA Network Open, suggests higher doses of buprenorphine were associated with lower rates of future behavioral health-related emergency department and inpatient care. RAND https://go.nih.gov/uw7ik5y
-
On Oct. 21, FDA & The National Institutes of Health will hold a joint public meeting, “Advancing Smoking Cessation: FDA and NIH Priorities.” It will be presented in a hybrid format, with an option for virtual attendance. Submit your request to provide in-person comment & register: https://lnkd.in/dfvQquCR
-
The National Institutes of Health's National Institute on Drug Abuse is seeking a Director for the Division of Neuroscience and Behavior to provide scientific executive leadership, direction, and vision for NIDA’s basic neuroscience and behavioral extramural research program of national and international scope focused on: 💠 the neurobiological mechanisms of substance use and addiction and 💠 the effects of illicit drugs on brain function through integrated research programs in genetics, systems neuroscience, behavioral and cognitive neuroscience, chemistry, neuropharmacology, and HIV/AIDS-related neuroimmunology. Learn more & apply online: https://lnkd.in/eESZrgGH The position is open until filled. The search committee will begin reviewing applications on November 4, 2024.
-
According to a 🆕 The National Institutes of Health-supported study, fewer than half of U.S. jails provide life-saving medications for opioid use disorder. The findings, published in JAMA Network Open, highlight critical gaps in treatment access in correctional facilities, where almost two-thirds of people have a substance use disorder. JCOIN Coordination and Translation Center NORC at the University of Chicago #nihHEALinitiative https://go.nih.gov/frCgs1R
-
🆕 Nora's Blog: NIDA Director Dr. Nora Volkow discusses how commercial interests are among the social determinants that contribute to substance use and addictive behaviors.
Commercial interests contribute to drug use and addiction
The National Institute on Drug Abuse (NIDA) on LinkedIn